Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens
- PMID: 11551413
- DOI: 10.1016/s0169-5002(01)00210-0
Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens
Abstract
A panel of 31 long-term non-small cell lung cancer (NSCLC) cell lines was examined for the expression of protein and/or mRNA transcripts for 11 distinct immune response related molecules or tumor associated antigens (TAA). To assess whether cytokine stimulation might up-regulate expression of the genes of interest, cells were cultured in 500 U/ml of gamma-interferon (gamma-IFN) for 48-72 h prior to analysis. Major histocompatibility complex (MHC) Class I antigens were detected by indirect immunofluorescence and were constitutively expressed on all of the cell lines. The average of the mean fluorescence intensity (MFI) measured 222+/-22. gamma-IFN stimulation produced a significant increase to 482+/-36. For MHC Class II only 7/31 cell lines (23%) exhibited constitutive expression, while gamma-IFN treatment had a dramatic effect and yielded 18/31 (58%) positive cell lines. The co-stimulatory molecules CD80 and CD86 were examined by direct immunofluorescence for cell surface expression and RT-PCR amplification for mRNA. CD80 protein was not detected at all, while an insignificant percentage of cells were positive (mean 2%) for CD86 in all cell lines tested. gamma-IFN had no apparent effect on CD80 or CD86 protein expression. Constitutive CD80 or CD86 mRNA levels were observed in 45 and 61% of the NSCLC lines, respectively. These percentages increased to 77% and 90% with gamma-IFN. Cell surface phenotypic analysis for TAA revealed positive populations in 28/31 cell lines (90%) for Her-2/neu, 18/31 (58%) for CEA and 8/31 (26%) for GD-2, with gamma-IFN having no effect. After gamma-IFN stimulation, RT-PCR amplification for Mage-1, -2, -3 and WT-1 detected mRNA in 33%, 33%, 44% and 70% of the cell lines, respectively. Overall, gamma-IFN stimulation led to the up-regulation of MHC Class I molecules and class II molecules as well as CD80 and CD86 mRNA transcripts. This survey represents the first comprehensive analysis of NSCLC cell lines for a variety of molecules that could play an important role in the generation of an NSCLC anti-tumor CD8+ cytotoxic T lymphocyte (CTL) response.
Similar articles
-
The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10.Cancer Immunol Immunother. 1996 Dec;43(4):213-9. doi: 10.1007/s002620050324. Cancer Immunol Immunother. 1996. PMID: 9003466
-
Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.Int Immunol. 1997 Jun;9(6):853-60. doi: 10.1093/intimm/9.6.853. Int Immunol. 1997. PMID: 9199968
-
Interferon-gamma differentially regulates CD80 (B7-1) and CD86 (B7-2/B70) expression on human Langerhans cells.Br J Dermatol. 1997 Jun;136(6):831-7. Br J Dermatol. 1997. PMID: 9217813
-
Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.Eur J Immunol. 1998 Jan;28(1):90-103. doi: 10.1002/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5. Eur J Immunol. 1998. PMID: 9485189
-
B7 family molecules: novel immunomodulators at the maternal-fetal interface.Placenta. 2002 Apr;23 Suppl A:S95-101. doi: 10.1053/plac.2002.0813. Placenta. 2002. PMID: 11978065 Review.
Cited by
-
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.Front Immunol. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465. eCollection 2023. Front Immunol. 2023. PMID: 37090727 Free PMC article. Review.
-
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Front Bioeng Biotechnol. 2022 Jun 22;10:797440. doi: 10.3389/fbioe.2022.797440. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35814023 Free PMC article. Review.
-
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.Front Immunol. 2022 Jun 2;13:903562. doi: 10.3389/fimmu.2022.903562. eCollection 2022. Front Immunol. 2022. PMID: 35720364 Free PMC article. Review.
-
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.J Immunother Cancer. 2022 Jan;10(1):e003897. doi: 10.1136/jitc-2021-003897. J Immunother Cancer. 2022. PMID: 35022195 Free PMC article.
-
Rapidly Growing Mycobacterium Species: The Long and Winding Road from Tuberculosis Vaccines to Potent Stress-Resilience Agents.Int J Mol Sci. 2021 Nov 29;22(23):12938. doi: 10.3390/ijms222312938. Int J Mol Sci. 2021. PMID: 34884743 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
